Clinical Scorecard: Evaluation of the Efficacy of Ciclosporin versus Sodium Hyaluronate Eye Drops in Managing Diabetes-Related Dry Eye Syndrome Following Vitrectomy
At a Glance
Category
Detail
Condition
Diabetes-Related Dry Eye Syndrome (DMDES)
Key Mechanisms
Ciclosporin promotes tear secretion and mucin production, improving tear film stability; Sodium Hyaluronate serves as an artificial tear substitute.
Target Population
Patients with type 2 diabetes mellitus undergoing vitrectomy for diabetic vitreous hemorrhage.
Care Setting
Ophthalmology department in a hospital setting.
Key Highlights
Ciclosporin (0.05%) eye drops showed greater improvement in tear film quality compared to sodium hyaluronate eye drops.
Significant improvements in non-invasive breakup time (NIBUT), tear meniscus height (TMH), and Schirmer I test (SIT) were observed at 1 month postoperatively in the CsA group.
Ciclosporin group demonstrated a decrease in corneal fluorescein staining scores, indicating less corneal epithelial damage.
Guideline-Based Recommendations
Diagnosis
Preoperative diagnosis of type 2 diabetes mellitus complicated by diabetic retinopathy and dry eye disease.
Management
Use 0.05% ciclosporin eye drops for improved outcomes in DMDES post-vitrectomy.
Monitoring & Follow-up
Assess NIBUT, TMH, SIT, and CFSS at 1 and 3 months postoperatively.
Risks
Potential for corneal epithelial damage if not monitored properly.
Patient & Prescribing Data
204 patients with DMDES post-vitrectomy.
Ciclosporin eye drops are more effective than sodium hyaluronate in improving tear film stability and reducing corneal staining.
Clinical Best Practices
Conduct thorough preoperative assessments for DMDES in diabetic patients.
Implement a structured follow-up protocol to monitor treatment efficacy and ocular surface health.
